Medtronic FDA Approval Marks a Turnaround in the Paclitaxel Story
Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for manufacturers and physicians this year, but an FDA approval this week marks a major step forward for this category of devices.
The agency approved Medtronic's IN.PACT AV drug-coated balloon for the treatment of failing arteriovenous access in patients with end-stage renal disease (ESRD) undergoing dialysis.
AV fistulae are created and used to enable hemodialysis for patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three ...
Source: MDDI - November 22, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news
AHA: Impella Use Up for PCI Patients Needing Heart Pump
THURSDAY, Nov. 21, 2019 -- Impella use is increasing for percutaneous coronary intervention (PCI) patients treated with mechanical circulatory support (MCS), although its use is associated with adverse events, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2019 Category: Pharmaceuticals Source Type: news
LimFlow Shows ‘PROMISE’ During VIVA
A firm that was labeled one of Medtech’s 16 Most Promising Private Companies by Canaccord Genuity earlier this year, has strong results from a study that will help with FDA approval. LimFlow recently announced positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the Percutaneous Deep Vein Arterialization (pDVA) System.
The Paris-based company presented the data during the Vascular Interventional Advances [VIVA] Conference held in Las Vegas, earlier this month. The company’s technology is used for the treatment of chronic limb-threatening ischem...
Source: MDDI - November 18, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
Study Casts Doubt on Angioplasty, Bypass for Many Heart Patients
However, the results of a large and long-awaited clinical trial suggests that, in most cases, these procedures may not have provided any benefit over medications and lifestyle changes. (Source: WebMD Health)
Source: WebMD Health - November 18, 2019 Category: Consumer Health News Source Type: news
Cheap, Older Gout Drug Could Be a Lifesaver After Heart Attack
In the new trial, colchicine reduced by as much as 34% a heart attack survivor's combined risk of either dying from heart disease or having cardiac arrest, a heart attack, a stroke or angioplasty. (Source: WebMD Health)
Source: WebMD Health - November 18, 2019 Category: Consumer Health News Source Type: news
Study Casts Doubt on Angioplasty, Bypass for Many Heart Patients
Title: Study Casts Doubt on Angioplasty, Bypass for Many Heart PatientsCategory: Health NewsCreated: 11/17/2019 12:00:00 AMLast Editorial Review: 11/18/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - November 18, 2019 Category: Cardiology Source Type: news
Study Casts Doubt on Angioplasty, Bypass for Many Heart Patients
SUNDAY, Nov. 17, 2019 -- Bypass operations, angioplasty and the placement of artery-opening stents: For decades, millions of Americans have undergone these expensive, invasive procedures to help treat clogged vessels.
However, the results of a large... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 17, 2019 Category: General Medicine Source Type: news
Big Study Finds Many Heart Procedures Won ’t Cut Risk of Having Heart Attack
This study clearly goes against what has been the common wisdom for the last 30, 40 years” and may lead to less testing and invasive treatment for such patients in the future, said Dr. Glenn Levine, a Baylor College of Medicine cardiologist with no role in the research. Some doctors still may quibble with the study, but it was very well done “and I think the results are extremely believable,” he said.
About 17 million Americans have clogged arteries that crimp the heart’s blood supply, which can cause periodic chest pain. Cheap and generic aspirin, cholesterol-lowering drugs and blood pressure medic...
Source: TIME: Health - November 16, 2019 Category: Consumer Health News Authors: ARILYNN MARCHIONE / AP Tags: Uncategorized onetime Research Source Type: news
Boston Scientific Touts Positive Data on Two Paclitaxel Devices
Boston Scientific announced positive data Tuesday for two paclitaxel devices during separate late-breaking clinical trial presentations at the annual Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for the drug-coated balloon manufacturers and physicians this year, but presentations like these could go a long way toward helping the market rebound.
To recap, paclitaxel balloons and stents received some bad press in late December 2018 after a meta-analysis showed...
Source: MDDI - November 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news
12 Innovations That Will Change Health Care and Medicine in the 2020s
Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace.
No one can predict the future, but it can at least be glimpsed in the dozen inventions and concepts below. Like the people behind them, they stand at the vanguard of health care. Neither exhaustive nor exclusive, the list is, rather, representative of the recasting of public health and medic...
Source: TIME: Health - October 25, 2019 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized HealthSummit19 technology Source Type: news
PCI, CABG for Left Main CAD Have Similar Five-Year Outcomes
FRIDAY, Oct. 4, 2019 -- Five-year rates of a composite outcome of death, stroke, and myocardial infarction are similar for patients with left main coronary artery disease following either percutaneous coronary intervention (PCI) or coronary artery... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2019 Category: Pharmaceuticals Source Type: news
No Increased Mortality With Paclitaxel Balloon Angioplasty in PAD No Increased Mortality With Paclitaxel Balloon Angioplasty in PAD
A new patient-level aggregate dataset from the LEVANT trials shows no increase in mortality for patients treated with paclitaxel-coated balloon angioplasty at 5 years of follow-up.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 2, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Less Bleeding With Ticagrelor Alone in High-Risk Patients
FRIDAY, Sept. 27, 2019 -- Ticagrelor alone results in less bleeding than ticagrelor plus aspirin among high-risk patients who have undergone percutaneous coronary intervention (PCI) and received dual antiplatelet therapy for three months, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 27, 2019 Category: Pharmaceuticals Source Type: news
First & #039;Artificial Meniscus & #039; Wins FDA Breakthrough Device Designation
U.S. patients who continue to suffer from knee pain after meniscus surgery, but are too young for total knee replacement may soon have a new treatment option. FDA has granted Active Implants' NUsurface meniscus implant a breakthrough device designation.
The artificial meniscus device is already available in Europe and, if cleared by FDA, would also be the first artificial meniscus in the United States.Â
Earlier this year Active Implants gained some attention from Needham & Co.'s Mike Matson, who included the company on a list of interesting private medtech companies.&Acir...
Source: MDDI - September 19, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Orthopedics Source Type: news
Short DAPT After DES: P2Y12 Monotherapy in, Aspirin out! Short DAPT After DES: P2Y12 Monotherapy in, Aspirin out!
A new study addresses the question of when aspirin can be safely discontinued in higher risk patients such as those undergoing complex percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
